mexiletine has been researched along with Action Tremor in 5 studies
Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.
mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The antiarrhythmic effects of the sustained release form of mexiletine (Mexitil-Perlongets) were evaluated in a double-blind placebo trial in 630 patients with recent documented myocardial infarction." | 9.05 | International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings. Impact Research Group. ( , 1984) |
| "Mexiletine was ineffective in 10 subjects." | 5.27 | Mexiletine in refractory ventricular arrhythmias. ( Fenster, PE; Kern, KB, 1983) |
| "The antiarrhythmic effects of the sustained release form of mexiletine (Mexitil-Perlongets) were evaluated in a double-blind placebo trial in 630 patients with recent documented myocardial infarction." | 5.05 | International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings. Impact Research Group. ( , 1984) |
| "Mexiletine was ineffective in 10 subjects." | 1.27 | Mexiletine in refractory ventricular arrhythmias. ( Fenster, PE; Kern, KB, 1983) |
| "SUN 1165 had no effect on clonic convulsions induced by pentetrazol and pictrotoxin in mice, while both mexiletine and lidocaine prolonged the duration of clonic convulsions." | 1.27 | General pharmacological studies on N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate. 1st communication: effect on the central nervous system. ( Hashimoto, Y; Hatta, M; Hattori, Y; Hirotsu, I; Ishihara, T; Kihara, T; Kitakaze, Y; Miyata, T; Nakamura, S; Takahama, K, 1988) |
| "Mexiletine was combined with a conventional type IA antiarrhythmic agent in 25 patients (49%)." | 1.27 | Intolerance and ineffectiveness of mexiletine in patients with serious ventricular arrhythmias. ( Bardy, GH; Fahrenbruch, CE; Graham, EL; Greene, HL; Poole, JE; Pulaski, WP; Werner, JA, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fenster, PE | 1 |
| Kern, KB | 1 |
| Haggman, DL | 1 |
| Maloney, JD | 1 |
| Morant, VA | 1 |
| Castle, LW | 1 |
| King-Rankine, M | 1 |
| Goormastic, M | 1 |
| Hirotsu, I | 1 |
| Kihara, T | 1 |
| Nakamura, S | 1 |
| Hattori, Y | 1 |
| Hatta, M | 1 |
| Kitakaze, Y | 1 |
| Takahama, K | 1 |
| Hashimoto, Y | 1 |
| Miyata, T | 1 |
| Ishihara, T | 1 |
| Poole, JE | 1 |
| Werner, JA | 1 |
| Bardy, GH | 1 |
| Graham, EL | 1 |
| Pulaski, WP | 1 |
| Fahrenbruch, CE | 1 |
| Greene, HL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Catheter Ablation for Ventricular Tachycardia in Patients With an Implantable Cardioverter Defibrillator (CALYPSO) PILOT TRIAL[NCT01576042] | 27 participants (Actual) | Interventional | 2012-05-31 | Terminated (stopped due to Main objectives of the study were met; consensus among investigators that continuing the study would not add new information beyond that already learned.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Records participants hospitalized for VT during the study (NCT01576042)
Timeframe: Baseline, 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 5 |
| Antiarrhythmic Medication | 7 |
Records participants who completed Month 3 Follow-Up Visit (NCT01576042)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 12 |
Records participants who completed Month 6 Follow-Up Visit (NCT01576042)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 7 |
| Antiarrhythmic Medication | 10 |
Records participants who had at least one of the efficacy outcome measurement (including death, hospitalization due to VT) (NCT01576042)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 14 |
Records participants who received study randomized treatment during the study (NCT01576042)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 14 |
Records participants who only received study treatment as randomized during the entire study (NCT01576042)
Timeframe: 6 month
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 6 |
| Antiarrhythmic Medication | 13 |
Records participants who received study treatment as randomized and later switched to other treatment arm during the study (NCT01576042)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 5 |
| Antiarrhythmic Medication | 1 |
Days from the date of the first study treatment to the date of first ICD recurrent therapy for VT. (NCT01576042)
Timeframe: Baseline, 6 months
| Intervention | Days (Mean) |
|---|---|
| Catheter Ablation | 70.1 |
| Antiarrhythmic Medication | 78.7 |
1 trial available for mexiletine and Action Tremor
| Article | Year |
|---|---|
International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings. Impact Research Group.
Topics: Adult; Aged; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical Trials as Topic; Delayed-A | 1984 |
4 other studies available for mexiletine and Action Tremor
| Article | Year |
|---|---|
Mexiletine in refractory ventricular arrhythmias.
Topics: Aged; Arrhythmias, Cardiac; Drug Evaluation; Electrocardiography; Female; Humans; Male; Mexiletine; | 1983 |
Mexiletine therapy in patients with chronic drug-resistant malignant ventricular arrhythmias. Clinical efficacy, safety, and side effects.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Arrhythmias, Cardiac; Chronic Disease; Death, Sudden; Dizz | 1986 |
General pharmacological studies on N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate. 1st communication: effect on the central nervous system.
Topics: Administration, Oral; Animals; Anti-Arrhythmia Agents; Body Temperature; Catalepsy; Cats; Central Ne | 1988 |
Intolerance and ineffectiveness of mexiletine in patients with serious ventricular arrhythmias.
Topics: Cardiac Pacing, Artificial; Disopyramide; Drug Therapy, Combination; Electrocardiography; Electrophy | 1986 |